Advanced search
Publication Cover
Infection and Drug Resistance Volume 12, 2019 - Issue
Submit an article Journal homepage
88
Views
3
CrossRef citations to date
0
Altmetric
Case Report

Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype

Georg von Massow1 Liver Unit, Liver Diseases – Viral Hepatitis, Vall d’Hebron Institut of Research (VHIR) – Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain
,
Damir Garcia-Cehic1 Liver Unit, Liver Diseases – Viral Hepatitis, Vall d’Hebron Institut of Research (VHIR) – Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain;2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
,
Josep Gregori1 Liver Unit, Liver Diseases – Viral Hepatitis, Vall d’Hebron Institut of Research (VHIR) – Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain;2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain;3 Roche Diagnostics S.L., Sant Cugat del Vallès, Barcelona, Spain
,
Francisco Rodriguez-Frias2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain;4 Biochemistry and Microbiology Department, VHIR-HUVH, Barcelona, Spain
,
María Dolores Macià5 Unidad de Microbiología Molecular, Servicio de Microbiología, Instituto de Investigación Sanitaria de les Illes Balears (IdISBa), Hospital Universitario Son Espases, Mallorca, Spain
,
Ana Escarda6 Digestive Department, Hospital Universitario Son Espases, Mallorca, Spain
,
Juan Ignacio Esteban1 Liver Unit, Liver Diseases – Viral Hepatitis, Vall d’Hebron Institut of Research (VHIR) – Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain;2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain;7 Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain
&
Josep Quer1 Liver Unit, Liver Diseases – Viral Hepatitis, Vall d’Hebron Institut of Research (VHIR) – Hospital Universitari Vall d’Hebron (HUVH), Barcelona, Spain;2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain;7 Medicine Department, Universitat Autònoma de Barcelona, Barcelona, SpainCorrespondence[email protected]
 show all
Pages 947-955 | Published online: 24 Apr 2019

References

  • United Nations-General Assembly. Global hepatitis report 2017. WHO; 2017 Available from: http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/.2017/p1-83ed.
  • Smith D. HCV classification. A web resource to manage the classifcation and genotype and subtype assignements of hepatits virus; 2018 Available from: https://talk.ictvonline.org/ictv_wikis/flaviviridae/w/sg_flavi/56/hcv-classification.
  • Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and assignment web resource. Hepatology. 2014;59:318–327. doi:10.1002/hep.2674424115039
  • Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992;66:3225–3229.1313927
  • Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol. 2012;26:487–503. doi:10.1016/j.bpg.2012.09.01123199507
  • Eltahla AA, Leung P, Pirozyan MR, et al. Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. Sci Rep. 2017;7:41719. doi:10.1038/srep4171928139734
  • EASL. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511. doi:10.1016/j.jhep.2018.03.02629650333
  • Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632. doi:10.1002/hep.2793426095927
  • Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504. doi:10.1016/j.jhep.2015.09.01126409317
  • Quer J, Gregori J, Rodriguez-Frias F, et al. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J Clin Microbiol. 2015;53:219–226. doi:10.1128/JCM.02093-1425378574
  • Ordeig L, Garcia-Cehic D, Gregori J, et al. New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors. J Gen Virol. 2018;99:97–102. doi:10.1099/jgv.0.00099629239718
  • Rodriguez-Frias F, Nieto-Aponte L, Gregori J, et al. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clin Microbiol Infect. 2017;23:775e1–775e6. doi:10.1016/j.cmi.2017.02.00728192235
  • Kuiken C, Combet C, Bukh J, et al. A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. Hepatology. 2006;44:1355–1361. doi:10.1002/hep.2137717058236
  • R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.
  • Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics. 2004;5:113. doi:10.1186/1471-2105-5-11315318951
  • Perales C, Chen Q, Soria ME, et al. Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant. Infect Drug Res. 2018;11:2207–2210.
  • Palanisamy N, Kalaghatgi P, Akaberi D, et al. Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals. Antivir Ther. 2018;23:485–493. doi:10.3851/IMP323729745936
  • Sorbo MC, Cento V, Di Maio V, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat. 2018;37:17–39. doi:10.1016/j.drup.2018.01.00429525636
  • Lawitz E, Yang JC, Stamm LM, et al. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor. Antivir Ther. 2018;23:325–334. doi:10.3851/IMP320229063860

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.